Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd

$GUJTHEMPharmaceuticalsNSEBSE

Gujarat Themis Biosyn Ltd (GUJTHEM) last traded at ₹410, a market capitalisation of ₹4,463 crore, on a P/E of 91.7. Over the past 52 weeks the stock has ranged between ₹225 and ₹479. Gujarat Themis Biosyn Ltd last reported results for the quarter ended Jun 2026, with sales of ₹44 crore and net profit of ₹11 crore. Figures are as of 25 Aug 2026 and are not real time.

Gujarat Themis Biosyn Ltd share price and key metrics

Current price
₹410
Market cap
₹4,463 cr
Stock P/E
91.7
ROE
%
ROCE
%
Dividend yield
0.16%
52w high / low
479/225

Metrics as of 25 Aug 2026. Not real time.

Gujarat Themis Biosyn Ltd quarterly results

Gujarat Themis Biosyn Ltd consolidated quarterly results, figures in ₹ crore
₹ croreJun 2025Mar 2026Jun 2026
Sales364444
Expenses222523
Operating profit141921
OPM %39%44%48%
Other income010
Interest022
Depreciation244
Profit before tax121415
Tax %25%24%27%
Net profit91111
EPS (₹)0.831.001.02

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Gujarat Themis Biosyn Ltd annual results

Gujarat Themis Biosyn Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2026
Sales166
Operating profit76
OPM %46%
Net profit47
EPS (₹)4.28

TTM is the trailing twelve months to the most recent quarter.

Gujarat Themis Biosyn Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
%
3 Years
%
TTM
%
Compounded Profit Growth
10 Years
%
5 Years
%
3 Years
%
TTM
%
Stock Price CAGR
10 Years
51%
5 Years
49%
3 Years
57%
1 Year
3%
Return on Equity
10 Years
%
5 Years
%
3 Years
%
Last Year
%

Gujarat Themis Biosyn Ltd shareholding pattern

Promoters held 70.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 1.76% and DIIs 1.17%.

Gujarat Themis Biosyn Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters70.87%70.87%70.87%70.87%70.87%70.87%70.86%70.87%
FIIs1.49%1.42%1.91%2.51%2.95%1.96%1.80%1.76%
DIIs1.17%1.17%1.17%1.17%1.17%1.17%1.17%1.17%
Public26.47%26.55%26.05%25.44%25.01%26.00%26.15%26.18%
No. of shareholders31,27130,93430,67328,94528,31927,32526,88627,010

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Gujarat Themis Biosyn Ltd corporate filings

  • Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Ltd has filed a disclosure regarding amendments to its Memorandum…

    Read the full analysis
  • Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Ltd has filed a disclosure regarding amendments to its Memorandum…

    Read the full analysis
  • Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAGM/EGMmedium impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Limited has received shareholder approval via postal ballot for two…

    Read the full analysis
  • Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAGM/EGMmedium impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Limited has successfully concluded its Extraordinary General…

    Read the full analysis
  • Shareholder Meeting / Postal Ballot-Outcome of EGMAGM/EGMmedium impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Limited has successfully concluded its Extraordinary General…

    Read the full analysis
  • Earnings Call TranscriptCompany Updatehigh impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn reported Q1 FY27 revenue of INR 43.8 crore, up 22.1% YoY, with…

    Read the full analysis
  • Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Ltd has formally submitted the audio recording of the investor and…

    Read the full analysis
  • Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Limited has released its un-audited standalone and consolidated…

    Read the full analysis
  • Announcement under Regulation 30 (LODR)-Investor PresentationCompany Updatehigh impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Limited (GTBL) delivered a robust performance in Q1 FY27, with…

    Read the full analysis
  • Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.08.2026Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Limited reported a strong performance for the quarter ended 30th…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sachin D PatelInsider Trading / SASTlow impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Limited has reported an inter-se transfer of 5,23,560 equity shares…

    Read the full analysis
  • Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Gujarat Themis Biosyn Ltd has issued an intimation regarding an upcoming analyst and…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Gujarat Themis Biosyn Ltd

Cruxal reads every Gujarat Themis Biosyn Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Gujarat Themis Biosyn Ltd (GUJTHEM) Results, Financials & Share Price | Cruxal